Showing 221-240 of 644 for: Cochrane Systematic Reviews > Psychiatric and substance abuse 
- Family therapy for depression
Cochrane Systematic Reviews, 31-Oct-2008
People with depression often experience interpersonal problems. Family therapy for depression is a widely used intervention, but it is unclear whether this is an effective therapy for the treatment of depression.
- Family-based programmes for preventing smoking by children and adolescents
Cochrane Systematic Reviews, 27-Feb-2015
There is evidence that family and friends influence children's decisions to smoke.
- Fluoxetine versus other types of pharmacotherapy for depression
Cochrane Systematic Reviews, 17-Jul-2013
Depression is common in primary care and is associated with marked personal, social and economic morbidity, thus creating significant demands on service providers. The antidepressant fluoxetine has been studied in many randomised controlled trials (RCTs)
- Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders
Cochrane Systematic Reviews, 10-Jun-2014
Long-acting depot injections of drugs such as flupenthixol decanoate are extensively used as a means of long-term maintenance treatment for schizophrenia.
- Fluphenazine (oral) versus placebo for schizophrenia
Cochrane Systematic Reviews, 12-Jun-2018
Fluphenazine is one of the first drugs to be classed as an 'antipsychotic' and has been widely available for five decades.
- Fluphenazine decanoate (depot) and enanthate for schizophrenia
Cochrane Systematic Reviews, 25-Feb-2016
Intramuscular injections (depot preparations) offer an advantage over oral medication for treating schizophrenia by reducing poor compliance. The benefits gained by long-acting preparations, however, may be offset by a higher incidence of adverse effects.
- Fluvoxamine versus other anti-depressive agents for depression
Cochrane Systematic Reviews, 30-Sep-2013
Fluvoxamine, one of the oldest selective serotonin reuptake inhibitors (SSRIs), is prescribed to patients with major depression in many countries. Several studies have previously reviewed the efficacy and tolerability of fluvoxamine for the treatment of m
- Folate for depressive disorders
Cochrane Systematic Reviews, 22-Apr-2003
There are a number of effective interventions for the treatment of depression. It is possible that the efficacy of these treatments will be improved further by the use of adjunctive therapies such as folate.
- Folic acid for fragile X syndrome
Cochrane Systematic Reviews, 7-Apr-2011
It has been argued that individuals with fragile X syndrome could have low folate levels in their bodies and that supplementing their dietary intake might remediate the adverse developmental and behavioural effects of the condition.
- Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people
Cochrane Systematic Reviews, 8-Oct-2008
Folate deficiency can result in congenital neural tube defects and megaloblastic anaemia. Low folate levels may be due to insufficient dietary intake or inefficient absorption, but impaired metabolic utilization also occurs.
- Follow-up for improving psychological well being for women after a miscarriage
Cochrane Systematic Reviews, 8-Feb-2012
Miscarriage is the premature expulsion of an embryo or fetus from the uterus up to 23 weeks of pregnancy and weighing up to 500 grams. International studies using diagnostic tools have identified that some women suffer from anxiety, depression and grief a
- Functional analysis-based interventions for challenging behaviour in dementia
Cochrane Systematic Reviews, 29-Dec-2011
Functional analysis (FA) for the management of challenging behaviour is a promising behavioural intervention that involves exploring the meaning or purpose of an individual’s behaviour. It extends the ‘ABC’ approach of behavioural analysis, to overcome th
- Galantamine for Alzheimer's disease and mild cognitive impairment
Cochrane Systematic Reviews, 3-Nov-2008
Galantamine is a specific, competitive, and reversible acetylcholinesterase inhibitor.
- Galantamine for vascular cognitive impairment
Cochrane Systematic Reviews, 25-Jan-2006
Vascular dementia represents the second most common type of dementia after that caused by Alzheimer's disease. Particularly in older patients, the combination of vascular dementia and Alzheimer's disease is common and is referred to as mixed dementia. The
- Gamma‐aminobutyric acid agonists for antipsychotic‐induced tardive dyskinesia
Cochrane Systematic Reviews, 17-Apr-2018
Chronic antipsychotic drug treatment may cause tardive dyskinesia (TD), a long-term movement disorder. Gamma-aminobutyric acid (GABA) agonist drugs, which have intense sedative properties and may exacerbate psychotic symptoms, have been used to treat TD.
- Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses
Cochrane Systematic Reviews, 17-Feb-2010
Chronic excessive alcohol consumption may lead to dependence, and to alcohol withdrawal syndrome (AWS) in case of abrupt drinking cessation. Gamma-hydroxybutyric acid (GHB) can prevent and suppress withdrawal symptoms, and improve the medium-term abstinen
- General physical health advice for people with serious mental illness
Cochrane Systematic Reviews, 28-Mar-2014
There is currently much focus on provision of general physical health advice to people with serious mental illness and there has been increasing pressure for services to take responsibility for providing this.
- Ginkgo biloba for cognitive impairment and dementia
Cochrane Systematic Reviews, 21-Jan-2009
Products of the maidenhair tree, Ginkgo biloba, have long been used in China as a traditional medicine for various disorders of health. A standardized extract is widely used in the West for the treatment of a range of conditions including memory and conce
- Glutamatergic drugs for schizophrenia
Cochrane Systematic Reviews, 31-Jan-2013
It has been shown that central nervous system dopamine can play a major role in the pathophysiology of schizophrenia. Brain glutamate is thought to mediate symptoms in schizophrenia due to the influence of glutamate neurons on the dopaminergic transmissio
- Gluten- and casein-free diets for autistic spectrum disorder
Cochrane Systematic Reviews, 2-Apr-2019
It has been suggested that peptides from gluten and casein may have a role in the origins of autism and that the physiology and psychology of autism might be explained by excessive opioid activity linked to these peptides. Research has reported abnormal l
